Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06972498) titled 'A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets' on May 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Condition:
Colorectal Cancer With Liver Metastasis
Intervention:
Drug: Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose
Recruitment Status: Not recruiting
Phase: Pha...